EMA Calls For Zinbryta's ‘Immediate’ Suspension After More Reports of Brain Disorders
Executive Summary
Biogen/AbbVie’s Zinbryta is already being withdrawn worldwide, but EMA now wants the MS drug recalled after mounting reports of serious brain disorders.
You may also be interested in...
42 New Substances Among 84 EU Approval Recommendations In 2018
The EMA’s CHMP recommended EU marketing authorization for a total of 84 new drugs in 2018, containing a total of 42 new active substances. They included the EU’s first two CAR-T cell therapies, Kymriah and Yescarta, which were also among the 21 orphan medicines to gain a positive opinion from the committee.
Zinbryta Global Withdrawal Driven In Part By Difficulty Of Safety Assessment
EMA safety investigation pushes decision as AbbVie, Biogen acknowledge 'characterizing the evolving benefit/risk profile … will not be possible going forward given the limited number of patients being treated.'
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.